NAFLD Studies & Patient Education
About Our Research
To help patients cope with NAFLD, which has yet to receive FDA-approved medications for treatment, our agency's industry-sponsored trials are providing opportunities for patients suffering from NAFLD to participate in our cutting-edge research that will vitally help identify new treatments and preventative methods for NAFLD.
We are currently focused on 3 types of studies:
-
NAFLD / NASH Non-Interventional Studies
-
NAFLD / NASH Treatment Trials
-
NASH Fibrosis Stage 3-4 Treatment Trials
NAFLD/NASH Non-Interventional Studies
Scroll through our ongoing studies to find out qualifications and details
Nadia Al Atrakchi, MD PhD (NALATRAKCHI@mgh.harvard.edu)
Pl: Kathleen Corey, MD (Kathleen.Corey@mgh.harvard.edu)
Pl: Kathleen Corey, MD (Kathleen.Corey@mgh.harvard.edu)
Nadia Al Atrakchi, MD PhD (NALATRAKCHI@mgh.harvard.edu)
Pl: Kathleen Corey, MD (Kathleen.Corey@mgh.harvard.edu)
PI: Tracey Simon, MD (TGSIMON@MGH.HARVARD.EDU)
Pl: Kathleen Corey, MD (Kathleen.Corey@mgh.harvard.edu); Takara Stanley, MD (TSTANLEY @mgh.harvard.edu)
Pl: Kathleen Corey, MD (Kathleen.Corey@mgh.harvard.edu)
NAFLD/NASH F0-3 Treatment Trials (Fibrosis Stage Study Specific)
Scroll through our ongoing trials and treatments to find out qualifications and details
NASH Fibrosis Stage 3-4 Treatment Trials
Aim of this study is to investigate the effects of Cenicriviroc versus placebo on the improvement of liver fibrosis, without the worsening of steatohepatitis
Pl: Kathleen Corey, MD (Kathleen.Corey@mgh.harvard.edu)
Pl: Kathleen Corey, MD (Kathleen.Corey@mgh.harvard.edu)